Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Q-VANT Biosciences enters Vaccine Research Master Agreement with Kansas State University

Q-Vant Biosciences

Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced that it has signed a Master Agreement with Kansas State University’s College of Veterinary Medicine to test and evaluate its saponin-based adjuvants in several of the university’s veterinary vaccines. Among the most highly regarded universities in the nation for veterinary vaccine science, K-State is home to the Biosecurity Research Institute, a world-renowned high-security containment facility. The Master Agreement will benefit Q-VANT and the university. The first project under the agreement will compare Q-VANT’s 100% sustainable saponin-based adjuvants to other known adjuvants utilizing K-State’s subunit classic swine fever (CSF) vaccine. This study will further the university’s instructional and research project objectives while advancing its vaccine development program. For Q-VANT, the study will serve to validate the safety and efficacy of the company’s Quillaja saponin-based adjuvants. “We’re excited to be working with Kansas State University and are looking forward to demonstrating the safety and efficacy of our adjuvants for widespread use in the global veterinary pharmaceutical market. The CSF field trial is the first of many we hope to perform with K-State using our 100% sustainable saponin-based adjuvants,” said Q-VANT’s Chief Commercial Officer, Juan Jose Allbarran. The CSF vaccine was developed by K-State professor Dr. Jishu Shi. Dr. Shi also serves as the director of the U.S.-China/Asia Center for Animal Health, where he and his team are working on novel vaccine and diagnostic strategies that are aimed at better control and prevention measures targeting swine infectious diseases. This includes porcine reproductive and respiratory syndrome (PRRS), classical swine fever virus (CSF), African swine fever (ASF) and other emerging viral diseases of swine. “This partnership is an exciting opportunity for all involved,” said Dr. Shi. “Our students will have the opportunity to take part in a research project that has the potential to have a major positive impact globally in animal vaccine development and usage.” About Q-VANT Biosciences Q-VANT is a privately held biosciences company that has solved the supply chain problem of QS-21 and other Quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The company's next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of QS-21 by more than 1,000 times - enabling the production of billions of doses annually to meet today's increasing global market demand. Led by a team with unrivaled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in Quillaja saponin supply chain, agronomy, extraction and purification, Q-VANT is the first company that is vertically integrated to combine a secured sustainable Quillaja raw material supply with pharma cGMP commercial-scale production of QS-21 and other saponin-based adjuvants. For more information, visit www.q-vant.com. Contact Details Hillary Lima +1 401-490-9700 q-vant@svmpr.com Company Website https://q-vant.com/

April 12, 2022 08:00 AM Eastern Daylight Time

CORRECTING and REPLACING Fine Hygienic Holding Continues to Lead on Progressive Female-Friendly Workplace Reforms with Pregnancy Loss Policy

Fine Hygienic Holding

In the last sentence boilerplate of release dated April 11, 2022, "multiple accolated and awards" corrected to read "multiple awards". The updated release reads: Fine Hygienic Holding Continues to Lead on Progressive Female-Friendly Workplace Reforms with Pregnancy Loss Policy Fine Hygienic Holding (FHH), the world-leading wellness group and manufacturer of hygienic paper products and long-term germ protection solutions, has yet again taken the initiative to introduce new female-friendly policies as part of its continuous workplace reforms which aim to provide the most inclusive and welcoming environment possible for all its employees. Demonstrating that the company is serious about bringing about positive change, it has updated its Parental Leave Policy to include provisions for miscarriage or stillbirth, across all its locations. FHH already has generous maternity leave provisions for working mothers who benefit from 16 weeks of paid leave, above what the International Labour Organization recommends, and it even offers 3 weeks of paid paternity leave, which puts it at the forefront not only in the MENA region but also globally. Employees are eligible for compassionate leave upon the unfortunate event of a female employee or a male employee’s spouse suffering a miscarriage or stillbirth. In both instances the employee is entitled to five days of paid leave, and females may take an additional five days of unpaid leave. This comes in line with FHH’s core values to lead with empathy and extend leave to women needing time to recover physically and emotionally, and to consider the needs of male partners as well. No other company in the region offers such a generous leave policy, with provisions for maternity, paternity, miscarriage or stillbirth, in addition to a monthly day off for females. James Michael Lafferty, FHH CEO, said, “Our company believes that – if we take care of the people, the business will take care of itself – which is why we are constantly on the lookout for practices that support our employees’ wellbeing, especially during pivotal moments in their lives. With our updated policy our aim is to live our values and support our employees through difficult times.” FHH adheres to the highest standards of HR practices with a strong emphasis on supporting and empowering parents within its workforce. It is worth mentioning that the company was recently recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. About Fine Hygienic Holding: Fine Hygienic Holding (FHH), one of the world’s leading wellness groups and MENA’s leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. Committed to becoming “the shining star of the Arab FMCG business world,” the Group focuses on wellness, sustainability, pioneering CSR programs, and state-of-the-art production processes. Fine Hygienic Holding offers a diverse array of award-winning products including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls, as well as away-from-home products to accommodate all types of private and public institutions, in addition to its advanced range of personal protective equipment (PPE) and long-lasting germ protection solutions, it also brings Nai natural iced teas and innovative nutritional supplements, Motiva, to the market. Along with multiple awards over the years, particularly for its products and CSR initiatives, the company was recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. Contact Details Rana Kawalit | │ Corporate Communication & PR Director Rkawalit@finehh.com Company Website https://www.finehh.com/

April 11, 2022 12:24 PM Eastern Daylight Time

Cannabis Education Event to Inform and Empower Consumers

MCR Labs

Local cannabis testing laboratory MCR Labs is hosting a consumer education event aimed at empowering consumers with the knowledge they need to make informed decisions about their cannabis purchases and consumption choices. The event, which is free and open to the public, will feature a presentation by MCR’s Vice President of Scientific Development Scott Churchill and InhaleMD’s President & CEO Dr. Jordan Tishler. Dr. Tishler is a Cannabinoid Specialist. “There is a lot of speculation out there on terms like ‘Total Active Cannabinoids’ and how factors like shelf life stability affect product quality,” said Churchill. “Our goal here is to help consumers develop a deeper understanding of cannabis so they can choose the right product for themselves.” MCR Labs provides analytical cannabis testing services to cultivators and product manufacturers. The data produced by these services, such as cannabinoid content, is often advertised on product labels. “It’s really important that patients understand how compounds like cannabinoids interact with their bodies,” said Dr. Tishler. “This can help them understand their medicine and work with their healthcare professionals to achieve optimal treatment.” Through his training in Internal Medicine and years of practice as an Emergency Physician, Dr. Tishler brings his knowledge, reason, and caring to patients at inhale MD, and through his advocacy work at the local and national levels. “What’s In Your Weed: The Educated Consumer” will be held this Thursday, April 14 from 6 to 8 p.m. at District Hall in Boston. Anyone interested in learning more or attending the event can find details on the event website. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details MCR Labs Alexandra Gomes +1 508-782-9772 alexandra@mcrlabs.com Company Website http://mcrlabs.com

April 11, 2022 11:08 AM Eastern Daylight Time

Red Sox pitcher Nathan Eovaldi to continue as Jimmy Fund Captain in 2022

Dana-Farber Cancer Institute and the Jimmy Fund

The Jimmy Fund announced today that Boston Red Sox pitcher, Nathan Eovaldi, will continue to serve as the Jimmy Fund Captain this season. In this role since 2021, Eovaldi is an ambassador for the Jimmy Fund, and helps to support and promote Dana-Farber Cancer Institute and the Jimmy Fund’s mission to defy cancer. The Red Sox have partnered with the Jimmy Fund since 1953, the longest and most successful charitable partnership in professional sports, and as Jimmy Fund Captain, Eovaldi will continue this long tradition. “I am thrilled to continue serving as this year’s Jimmy Fund Captain as it is a role that I am honored to have. I was fortunate to participate in last year’s WEEI/NESN Jimmy Fund Radio-Telethon and met many families who were so inspirational in telling their cancer journeys,” said Eovaldi. “I enjoy sharing the important Jimmy Fund and Dana-Farber mission and look forward to meeting other adult and pediatric patients and helping to raise awareness and funds for a cause that I, and the entire Red Sox organization, hold so close.” Every year, a Boston Red Sox player serves as the Jimmy Fund Captain, attending fundraising events, visiting patients, building support and raising funds for cancer care and research at Dana-Farber. Each dollar raised by the Jimmy Fund supports The Dana-Farber Campaign, the Institute’s ambitious, multi-year fundraising effort to prevent, treat, and defy cancer through revolutionary science, extraordinary care, exceptional expertise, and essential opportunities—saving more lives than ever before. “As the Jimmy Fund Captain, Nate has continued the tradition of distinguished Red Sox players who have made an incredible impact on Dana-Farber through the Jimmy Fund,” said Larry Lucchino, Chairman of the Jimmy Fund, Trustee of Dana-Farber Cancer Institute, Chairman/Principal Owner of the Worcester Red Sox, and President/CEO Emeritus of the Boston Red Sox. “I am excited to see Nate’s involvement grow as we continue to shift back to hosting in-person fundraisers.” Past Jimmy Fund Captains include Mitch Moreland, Brock Holt, Pablo Sandoval, Will Middlebrooks, David Ross, Jarrod Saltalamacchia, Daniel Bard, Clay Buchholz, and Tim Wakefield. Grassroots community fundraising is the heart and soul of the Jimmy Fund—thousands of people organizing bake sales, lemonade stands, runs, walks, golf tournaments, dances, auctions, softball games, and more, bringing their communities together to help Dana-Farber save lives. Some upcoming Jimmy Fund fundraisers include: - Strike Out Cancer with the Jimmy Fund - New this year, Red Sox fans can help to strike out cancer all season long. Pledge a donation of any amount for each Red Sox win this season, win great prizes, and help the Jimmy Fund and Dana-Farber defy cancer. Every dollar raised through Strike Out Cancer with the Jimmy Fund supports cancer research and care at Dana-Farber. - Jimmy Fund Scooper Bowl® Presented by Valvoline Instant Oil Change SM – Jimmy Fund Scooper Bowl®, the nation’s largest all-you-can-eat ice cream festival, is taking place in a new location, Patriot Place in Foxborough, Mass., this year on Saturday, June 18 th. The event will feature ice cream and frozen yogurt flavors from fan-favorite brands as well as musical entertainment, kids activities, and much more. - John Hancock Fenway Fantasy Day - Help the Jimmy Fund give Dana-Farber patients the chance of a lifetime to bat and field at Boston’s beloved ballpark during this year’s John Hancock Fenway Fantasy Day. By sending a patient to this year’s event, fans are giving cancer patients an extra special experience, while raising funds for pediatric and adult cancer care and research at Dana-Farber. About the Jimmy Fund The Jimmy Fund, established in Boston in 1948, is comprised of community-based fundraising events and other programs that, solely and directly, benefit Dana-Farber Cancer Institute’s lifesaving mission to provide compassionate patient care and groundbreaking cancer research for children and adults. The Jimmy Fund is an official charity of the Boston Red Sox, the Massachusetts Chiefs of Police Association, the Pan-Mass Challenge, and the Variety Children's Charity of New England. Since 1948, the generosity of millions of people has helped the Jimmy Fund save countless lives and reduce the burden of cancer for patients and families worldwide. Follow the Jimmy Fund on Facebook, Twitter and Instagram: @TheJimmyFund. Contact Details Dana-Farber Cancer Institute Molly McHale +1 617-512-8357 molly_mchale@dfci.harvard.edu

April 11, 2022 08:00 AM Eastern Daylight Time

Image

Fine Hygienic Holding Continues to Lead on Progressive Female-Friendly Workplace Reforms with Pregnancy Loss Policy

Fine Hygienic Holding

Fine Hygienic Holding (FHH), the world-leading wellness group and manufacturer of hygienic paper products and long-term germ protection solutions, has yet again taken the initiative to introduce new female-friendly policies as part of its continuous workplace reforms which aim to provide the most inclusive and welcoming environment possible for all its employees. Demonstrating that the company is serious about bringing about positive change, it has updated its Parental Leave Policy to include provisions for miscarriage or stillbirth, across all its locations. FHH already has generous maternity leave provisions for working mothers who benefit from 16 weeks of paid leave, above what the International Labour Organization recommends, and it even offers 3 weeks of paid paternity leave, which puts it at the forefront not only in the MENA region but also globally. Employees are eligible for compassionate leave upon the unfortunate event of a female employee or a male employee’s spouse suffering a miscarriage or stillbirth. In both instances the employee is entitled to five days of paid leave, and females may take an additional five days of unpaid leave. This comes in line with FHH’s core values to lead with empathy and extend leave to women needing time to recover physically and emotionally, and to consider the needs of male partners as well. No other company in the region offers such a generous leave policy, with provisions for maternity, paternity, miscarriage or stillbirth, in addition to a monthly day off for females. James Michael Lafferty, FHH CEO, said, “Our company believes that – if we take care of the people, the business will take care of itself – which is why we are constantly on the lookout for practices that support our employees’ wellbeing, especially during pivotal moments in their lives. With our updated policy our aim is to live our values and support our employees through difficult times.” FHH adheres to the highest standards of HR practices with a strong emphasis on supporting and empowering parents within its workforce. It is worth mentioning that the company was recently recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. Fine Hygienic Holding (FHH), one of the world’s leading wellness groups and MENA’s leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. Committed to becoming “the shining star of the Arab FMCG business world,” the Group focuses on wellness, sustainability, pioneering CSR programs, and state-of-the-art production processes. Fine Hygienic Holding offers a diverse array of award-winning products including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls, as well as away-from-home products to accommodate all types of private and public institutions, in addition to its advanced range of personal protective equipment (PPE) and long-lasting germ protection solutions, it also brings Nai natural iced teas and innovative nutritional supplements, Motiva, to the market. Along with multiple accolated and awards over the years, particularly for its products and CSR initiatives, the company was recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. Contact Details Rana Kawalit | │ Corporate Communication & PR Director Rkawalit@finehh.com Company Website https://www.finehh.com/

April 11, 2022 02:59 AM Eastern Daylight Time

Psychedelic Pharmaceutical Startup Ninnion Announces Patent Filings and Development of NIN-S119 for Ischemic Stroke

Ninnion

Ninnion, a clinical-stage pharmaceutical company focused on developing next-generation psychedelic therapeutics, today announced the commencement of a first-of-its-kind pre-clinical development of NIN-S119. NIN-S119 is a proprietary, short-acting substituted tryptamine to treat patients recovering from ischemic stroke. It would be the first drug of its kind in the treatment of stroke, potentially making it eligible for Breakthrough Therapy designation by the FDA, a designation that can accelerate the development timeline. “Ninnion saw a big opportunity to develop NIN-S119, as there are no approved drug therapies for patients recovering from a stroke. It will be used in conjunction with physical/occupational therapy to enhance stroke recovery by inducing neuroplasticity – meaning it induces the formation of new connections between nerve cells in the brain. This sort of brain ‘rewiring’ could prove beneficial for stroke recovery by creating new brain circuitry that could restore function to brain areas damaged by stroke,” said Bill W Massey, Chief Development Officer of Ninnion. While drugs of this class that produce neuroplastic effects can induce psychedelic experiences (e.g. LSD, mescaline, DMT, etc.), one major benefit of NIN-S119 is that even though it's in this class of drugs, it could potentially be administered in low doses that do not produce these experiences. This would make NIN-S119 much easier to use clinically, reducing the time and effort of clinical staff and opening the potential for administration by the patient at home. “After experiencing multiple health issues, including three strokes in one year, I began researching and reading all about how to repair the brain through the neuroplasticity and neurogenesis effects of psychedelics. We created Ninnion to not only develop a new way to treat strokes but more importantly, to bring these drugs to market in a responsible way. The way psychedelic therapies are set up now is not helpful for the payer-reimbursed market. We want to create therapies that are accessible and affordable; patients should not have to pay thousands of dollars for therapies out of pocket. We’re encouraged by recent patent approvals for the development and delivery of new psychedelic therapies and we’re looking forward to advancing our clinical trials and continuing to develop other molecules in our pipeline,” said Jeremy M Caudill, Founder, and CEO of Ninnion. Ninnion’s research and development efforts currently focus on advancing next-generation psychedelic therapies, which will ultimately empower patients with more accessible and affordable treatment opportunities. To find out more about the study and Ninnion’s NIN-S119 molecule, visit www.ninnion.com/. About Ninnion Headquartered in Austin, Texas, Ninnion is a pharmaceutical company on a mission to build a fully integrated pharmaceutical psychedelics eco-system leveraging the latest AI drug discovery, development, cGMP manufacturing, commercialization, patient clinics and specialty pharmacy distribution network designed for the next frontier of psychedelic medicine. Focused on the payer-reimbursed market, Ninnion has begun developing a pipeline of next generation psychedelic therapies with a clinical focus on brain injury, chronic pain, inflammation, and addiction disorders. To learn more, visit www.ninnion.com. Contact Details Jive PR + Digital Ashley Areeda +1 734-891-4013 aareeda@jiveprdigital.com

April 07, 2022 11:33 AM Eastern Daylight Time

AIHM Announces 2022 “People, Planet, Purpose” Conference, Oct. 28-30

Academy of Integrative Health and Medicine

Registration is now open for the Academy of Integrative Health and Medicine ’s (AIHM) annual “People. Planet. Purpose.” conference to be held October 28-30 at the Paradise Point Resort & Spa in San Diego. AIHM is also offering a virtual experience for those unable to attend in person. This year’s conference, entitled “Disruptive Innovation + the Future of Health” brings together leaders in health and medicine from across the globe to talk about the latest research-based integrative techniques and strategies. Deepak Chopra, MD, one of the best-known figures in integrative medicine, is among the featured speakers. “We are thrilled to be back in person this year for this incredible experience,” said AIHM Executive Director Tabatha Parker, ND. “Throughout history, pioneering innovators have made giant leaps in health. Now it’s our time in integrative healthcare to lead the innovation.” Attendees will engage in lively discussions and learn tools for implementing integrative medicine best practices with their own patients. Previous conference attendees have included medical doctors, functional medicine doctors, osteopathic doctors, naturopathic doctors, chiropractors, acupuncturists, physician assistants, advanced practice nurses, registered nurses, licensed dietitian nutritionists, midwives, pharmacists, dentists, licensed massage therapists, health coaches, and many more from across the U.S. and around the world. “AIHM’s conference is like no other conference. It’s an immersive experience alongside like-minded practitioners who are all striving to make a difference for people and the planet,” commented Parker. “Attendees not only learn from experts, they expand their minds, enhance their spirits and build a community.” To learn more or to register, visit aihm.org/conference. Founded in 1978, the Academy of Integrative Health and Medicine (AIHM) is the leading interprofessional organization for traditional, complementary and integrative health practitioners worldwide. In 2001, AIHM merged with the Academic Collaborative of Integrative Health (ACIH). Together, they are working to advance integrative health on a global scale and transform health and wellness through education, leadership, collaboration, research and advocacy. For more information, visit aihm.org or follow @aihmglobal on Facebook, Instagram, and Twitter. Contact Details Carol Stevenson +1 661-713-6879 carol@growthledge.com Company Website https://aihm.org

April 07, 2022 10:00 AM Eastern Daylight Time

COD Mammography Program Acquires Cutting-Edge, Hospital-Grade Equipment

College of DuPage

Mammography program students at College of DuPage now have access to more specialized training, thanks for the addition of new field-specific equipment. The innovative digital technology, Hologic Tomosynthesis 2D and 3D mammography machines, typically are available at hospitals and clinical settings and rarely on a college campus, said COD Diagnostic Medical Imaging Assistant Professor and Mammography Program Chair Sue Dumford. “The new equipment gives students an added advantage to be able to practice their skills in the classroom before having to use it on real patients during clinical rotations at hospitals and clinics,” she said. “Students will be able to practice on other classmates as well as on model torsos with soft breasts. Having the machines in front of students also allows us to teach about quality assurance and quality control.” The Mammography program at COD is a one-semester post-radiography advanced certificate program available to graduates of an accredited Radiography program. Many of the students enrolled in the Mammography program are graduates of COD’s two-year Radiography program. "I’m proud to say that we maintain a 100 percent American Registry of Radiologic Technologists registry pass rate and that our graduates are recognized as excellent entry-level mammographers,” Dumford said. Tara Logan decided to pursue a career in mammography after working at the front desk of a general surgery office. “One of the doctors in my office was a breast surgeon,” she said. “Every day he worked with breast cancer patients, and I will never forget how he made them feel. When people are going through some of the toughest days of their life, they need someone to lean on, and I wanted to be that person for them.” Logan graduated from COD’s Radiography program in 2020 earning an Associate in Applied Science in Diagnostic Medical Imaging before earning an advanced certificate in Mammography in 2021. “The program truly prepared me for a long career in breast imaging, and I’m so lucky to have been a part of both COD’s Radiography and Mammography programs,” she said. “With the two mammography units, I was able to learn correct positioning skills and then go out into the field and practice on real patients. Cancer screening is something that will always be needed, and your patients will always need you. Apply to the program and start making a difference in the way females feel about health care.” Learn more about the COD Mammography program. Learn more about COD’s Radiography program. Contact Details College of DuPage Angela Mennecke +1 630-942-3134 menneckea@cod.edu

April 07, 2022 08:00 AM Central Daylight Time

Image

Ben Wright, Rob Wellner, and Velocity Global receive First Descents’ Horizon Line Award for Leadership Support of MS Programming

Velocity Global

First Descents awards Ben Wright and Rob Wellner the Horizon Line Award at the 15th Annual First Descents Ball in recognition of Velocity Global’s visionary support of First Descents’ Multiple Sclerosis (MS) programming. “When I was diagnosed with MS 13 years ago, it turned my life upside down,” shares Rob Wellner, Velocity Global’s Chief Revenue Officer. “While medical treatments for MS have improved over time, psychosocial opportunities for those living with this diagnosis still remain limited. I’m honored to help enable these life-changing programs for the MS community in partnership with First Descents, and to be a part of a company dedicated to scaling our philanthropy for meaningful causes as we grow.” Each year, First Descents presents its highest honor - the Horizon Line Award - at the First Descents Ball to an individual or organization who dedicates their time, guidance, and wisdom to First Descents, asking nothing in return. In kayaking, one of our flagship outdoor programs, the horizon line is where the river descends into rapids not viewable by the paddler. At this point, the paddler must rely on his or her skills, tenacity, and the dedicated support of teammates. Over the past two decades, First Descents has experienced countless rapids and milestones in its history, and the team has relied on generous and selfless people and partners, like the entire Velocity Global team, to allow them to charge confidently ahead. “It’s a true honor to receive the Horizon Line Award on behalf of the entire Velocity Global team that puts us in the position to support First Descents and the young adult MS community. I’ve witnessed the transformative and healing power of adventure on their programs, including the very first MS program First Descents provided in 2018,” says Ben Wright, Founder and CEO of Velocity Global. “Service is one of the values we live by in our company, and First Descents embodies service to the full wellbeing of young adults living with MS. I’m proud of our partnership and the opportunity to support their mission in any way we can.” Velocity Global and First Descents have shared a special partnership since 2014 when the two Colorado-based companies became office neighbors at INDUSTRY Denver. Quickly bonding, Velocity Global employees now volunteer annually at First Descents’ programs and fundraisers, including the Ragnar Trail Relay Snowmass and TransRockies Run. In 2018, Velocity Global contributed $150,000 to pilot MS programming which began with a whitewater kayaking experience in Tarkio, Montana. In 2021, Velocity Global announced a transformative $1 million contribution to expand adventure programs for young adults with MS. “This year, we were honored to present Ben, Rob, and the entire Velocity Global team with our prestigious Horizon Line Award. We’ve long believed that our programs can serve populations beyond oncology. Ben and Rob shared this vision, and provided us with the generous funding, clinical connections, and support to extend the healing power of adventure to the MS community,” notes Ryan O’Donoghue, CEO, First Descents. “Their support will help us to serve hundreds of young adults living with MS in the coming years while building meaningful partnerships with patient advocacy groups and neurology clinics nationwide.” First Descents has served 57 MS participants across six programs since launching their pilot MS program in 2018. First Descents aims to serve more than 225 MS participants over the next three years. About Velocity Global Velocity Global accelerates the future of work for anyone, anywhere, anyhow. Its Global Work Platform™ simplifies the employer and talent experience through its proprietary cloud-based talent management technology, backed by personalized expertise and unmatched global scale. The platform offers a full suite of talent solutions, including global Employer of Record and Contractor Management, to help companies onboard, manage, and pay talent in more than 185 countries and all 50 United States. Thousands of brands rely on Velocity Global to build international teams without the cost or complexity of setting up foreign legal entities or state registrations. Velocity Global was named a "Leader" in Global Employer of Record Services by prominent analyst firm NelsonHall. Founded in 2014, the company has hundreds of employees across six continents. For more information, visit velocityglobal.com. About First Descents First Descents (FD) is a leader in adventure-based healing. Through outdoor adventure, community building, and lifestyle development, FD improves long-term survivorship and quality of life for young adults impacted by cancer, multiple sclerosis, and other serious health conditions. Headquartered in Denver, First Descents has served more than 10,000 participants over the last 20 years. Beginning in 2020, First Descents launched programs for healthcare workers on the frontlines of COVID-19. All services are fully-adaptive and free of charge. A Guidestar Platinum-ranked nonprofit, First Descents has been recognized on CNN Heroes and Outside Magazine’s Best Places to Work. Contact Details Velocity Global Anja Koltes +1 720-650-4348 news@velocityglobal.com First Descents Becca Rohrer +1 828-712-5927 becca.rohrer@firstdescents.org Company Website https://velocityglobal.com/

April 06, 2022 05:20 PM Eastern Daylight Time

Image

1 ... 232 233 234 235 236 ... 310